Welcome to our dedicated page for Bitwise MARA Option Income Strategy ETF news (Ticker: IMRA), a resource for investors and traders seeking the latest updates and insights on Bitwise MARA Option Income Strategy ETF stock.
Bitwise MARA Option Income Strategy ETF (IMRA) reports fund updates tied to monthly distributions for Bitwise's Option Income Strategy ETF suite. News for the fund centers on distribution per share, distribution rate, 30-day SEC yield, payment dates, return of capital treatment, expenses, and performance periods.
Fund updates also describe risks associated with the option-income approach, including derivative instruments, leverage, issuer-specific volatility, and differences between derivatives and direct holdings of traditional securities.
Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical firm, announced participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022. CEO Rahul Ballal, Ph.D., will partake in a Fireside Chat at 3:40 p.m. ET, focusing on the company’s advancements in rare hemoglobin disorders. Imara is progressing with tovinontrine (IMR-687), a treatment for sickle cell disease and beta-thalassemia in Phase 2b trials, and plans to initiate another trial in heart failure (HFpEF) by Q2 2022. Further details available on Imara’s website.
Imara Inc. (Nasdaq: IMRA) has received FDA approval for its investigational new drug application for tovinontrine (IMR-687) targeting heart failure with preserved ejection fraction (HFpEF). A Phase 2 trial, set to begin in Q2 2022, will evaluate its efficacy in patients aged 45 and older with persistent HFpEF symptoms and high PDE9 expression. The trial will involve 170 patients and assess primary endpoints such as NT-proBNP changes. The therapy aims to enhance cGMP levels, potentially improving symptoms in patients with coexisting hemoglobin disorders.
Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company, will be presenting at the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. The pre-recorded presentation will be available on January 10 at 7:00 AM ET on their website. Imara is focused on developing therapeutics for rare genetic disorders, advancing tovinontrine (IMR-687) for sickle cell disease and beta-thalassemia, and IMR-261 as an Nrf2 activator.
Imara Inc. presents data on IMR-261, a novel Nrf2 activator, at the ASH Annual Meeting, demonstrating its potential in treating sickle cell disease (SCD) and beta-thalassemia. In preclinical studies, high doses showed a 7-fold increase in fetal hemoglobin (HbF) and an approximately 3-fold increase in F-cells compared to placebo. Additionally, IMR-261 decreased markers of hemolysis and reduced vaso-occlusive crises (VOCs). The company seeks to further explore IMR-261’s applications beyond hemoglobin disorders, indicating robust preclinical data and promising next steps for development.
Imara Inc. (Nasdaq: IMRA) released positive 12-month data from its Phase 2a open-label extension trial for tovinontrine in treating sickle cell disease (SCD). The trial demonstrated a 38% reduction in the annualized rate of vaso-occlusive crises (VOCs) among patients, with stable rates reported during treatment. Tovinontrine was well-tolerated, with no significant adverse events. Additionally, preclinical data highlighted its effectiveness in beta-thalassemia. The company anticipates initial VOC data from its Ardent Phase 2b trial in Q1 2022.
Imara Inc. (Nasdaq: IMRA) has announced a change in the primary endpoint for its Ardent Phase 2b clinical trial of tovinontrine (IMR-687) in patients with sickle cell disease, following a recommendation from the FDA. The new primary endpoint will focus on the annualized rate of vaso-occlusive crises (VOCs), while fetal hemoglobin (HbF) response remains a secondary endpoint. No changes to the trial's conduct or size are planned. The first analysis of VOC rates is anticipated in Q1 2022, with final data expected in H2 2022. Tovinontrine has received various designations from the FDA and the European Commission.
Imara Inc. (Nasdaq: IMRA) announced positive interim data from its Forte Phase 2b clinical trial of tovinontrine in transfusion-dependent beta-thalassemia patients. Interim analysis showed a favorable trend in transfusion burden reduction at higher doses, with a notable safety profile. Of 43 subjects, 54% had a severe genotype, and the majority of those receiving higher doses experienced a significant decrease in transfusion needs. The trial continues, with expected efficacy results in Q1 2022. The FDA has granted several designations for tovinontrine, highlighting its therapeutic potential.
Imara Inc. (Nasdaq: IMRA) has announced significant updates regarding its clinical trials and financial results for Q3 2021. The company expects to reveal interim analysis data from the Phase 2b trials of tovinontrine (IMR-687) for sickle cell disease and beta-thalassemia in Q4 2021 and Q1 2022, respectively. Imara introduced IMR-261, a new Nrf2 activator, and is set to commence a Phase 2 trial for heart failure in 2022. Financially, Imara reported a net loss of $13.6 million, with cash reserves of $102.8 million, sufficient to fund operations into Q1 2023.
Imara Inc. (Nasdaq: IMRA) has announced preclinical data demonstrating the efficacy of tovinontrine (IMR-687) in three mouse models of heart failure with preserved ejection fraction (HFpEF). The study showed that tovinontrine effectively prevented cardiac hypertrophy and renal dysfunction, marking it as a promising option for HFpEF treatment. Imara also appointed Toni Bransford, M.D., as Vice President of Clinical Development to lead a Phase 2 trial for HFpEF, expected to start in 2022. The data will be presented at the American Heart Association Scientific Sessions on November 13, 2021.
Imara Inc. (Nasdaq: IMRA) will host a conference call and webcast on November 9, 2021, at 8:30 a.m. ET to discuss its financial results for Q3 2021, ending September 30, 2021.
The event will cover recent business highlights and can be accessed by calling 1 (833) 519-1307 (U.S.) or +1 (914) 800-3873 (international) with conference ID 1235955. The live webcast will be available on the company's website, with a replay archived afterward.
Imara focuses on developing therapeutics for rare genetic disorders related to hemoglobin, including sickle cell disease and beta-thalassemia.